MIRELANCT07896421
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Treatment Duration of MIRV Among Participants With Platinum-Resistant FRα-Positive Ovarian Cancer
Timeframe: Up to approximately 18 months
Arms and interventions
Mirvetuximab Soravtansine (MIRV)
Participants with FRα positive platinum-resistant ovarian, primary peritoneal or fallopian tube cancer and are scheduled to receive treatment with MIRV in accordance with the local label of the participating country.
Sites
1 site in 1 country
- Medizinische Universitaet Wien /ID# 282657Vienna, Austria